Dyne Therapeutics, Inc.
General ticker "DYN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.6B (TTM average)
Dyne Therapeutics, Inc. follows the US Stock Market performance with the rate: 32.1%.
Estimated limits based on current volatility of 3.6%: low 19.31$, high 20.76$
Factors to consider:
- Total employees count: 191 (+35.5%) as of 2024
- Top business risk factors: Operational and conduct risks, Limited operating history, Product failure, Labor/talent shortage/retention, Strategic risks and growth management
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [13.68$, 34.46$]
- 2025-12-31 to 2026-12-31 estimated range: [9.67$, 25.50$]
Financial Metrics affecting the DYN estimates:
- Negative: with PPE of -7.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -12.93 <= 0.33
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 91.12 > 63.39
- Negative: -0.75 < Inventory ratio change, % of 0
- Negative: negative Industry operating cash flow (median)
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
Short-term DYN quotes
Long-term DYN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $170.96MM | $242.16MM | $343.89MM |
| Operating Income | $-170.96MM | $-242.16MM | $-343.89MM |
| Non-Operating Income | $2.86MM | $6.22MM | $26.47MM |
| R&D Expense | $142.76MM | $210.76MM | $281.41MM |
| Income(Loss) | $-168.10MM | $-235.94MM | $-317.42MM |
| Profit(Loss)* | $-168.10MM | $-235.94MM | $-317.42MM |
| Stockholders Equity | $252.36MM | $91.29MM | $629.84MM |
| Assets | $306.32MM | $165.08MM | $691.23MM |
| Operating Cash Flow | $-153.65MM | $-188.16MM | $-292.37MM |
| Capital expenditure | $3.07MM | $0.73MM | $2.38MM |
| Investing Cash Flow | $87.20MM | $83.31MM | $-204.08MM |
| Financing Cash Flow | $37.39MM | $54.32MM | $809.89MM |
| Earnings Per Share** | $-3.23 | $-3.95 | $-3.37 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.